Name: Latest research reports of Alivus Life Sciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Alivus Life Sciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Alivus Life Sciences Ltd.

NSE: ALIVUS | BSE: 543322 | ISIN: INE03Q201024 | Industry: Pharmaceuticals
| Mid-range Performer

1014.6000 -7.60 (-0.74%)

NSE Jul 11, 2025 15:31 PM

Volume: 82,798

Alivus Life Sciences Ltd.

27 Jan 2023

1014.60

-0.74%

Glenmark Life Sciences (BUY): Sequential recovery in API business

Buy: Alivus Life Sciences Ltd.

Target

BOB Capital Markets Ltd.

Q3 revenue up 6% QoQ to Rs 5.4bn supported by sequential recovery in API business to parent and PLI benefits

Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.